内容紹介
Summary
A 56-year-old women underwent retroperitoneal leiomyosarcoma resection in December 2011. In July 2015, CT showed multiple liver metastases, and she received first-line chemotherapy treatment with doxorubicin. After 2 courses of doxorubicin, her performance status deteriorated; therefore, she was treated with pazopanib as second-line chemotherapy. PFS with pazopanib was 5 months and that with eribulin was 2.5 months. She was then treated with trabectedin as fourth-line chemotherapy from July 2016. The liver metastases reduced, and the disease was controlled for 1 year and 6 months following administration of trabectedin. We continue to treat this patient with trabectedin, and no serious side effects have been observed.
要旨
症例は56歳,女性。2011年12月に後腹膜平滑筋肉腫を切除後,2015年7月のCT検査で多発肝転移再発を認め,ドキソルビシン単剤による治療を開始した。有害事象によるperformance status低下にて,2コースでパゾパニブへ変更した。その後,二次治療のパゾパニブ5か月,三次治療のエリブリンは2.5か月で病勢進行を認めた。2016年7月より四次治療のトラベクテジンによる加療を開始し1年6か月が経過しているが,多発肝転移巣の一部は縮小も認め,特に重篤な有害事象はなく現在も治療継続中である。文献的な考察も加え報告する。
目次
A 56-year-old women underwent retroperitoneal leiomyosarcoma resection in December 2011. In July 2015, CT showed multiple liver metastases, and she received first-line chemotherapy treatment with doxorubicin. After 2 courses of doxorubicin, her performance status deteriorated; therefore, she was treated with pazopanib as second-line chemotherapy. PFS with pazopanib was 5 months and that with eribulin was 2.5 months. She was then treated with trabectedin as fourth-line chemotherapy from July 2016. The liver metastases reduced, and the disease was controlled for 1 year and 6 months following administration of trabectedin. We continue to treat this patient with trabectedin, and no serious side effects have been observed.
要旨
症例は56歳,女性。2011年12月に後腹膜平滑筋肉腫を切除後,2015年7月のCT検査で多発肝転移再発を認め,ドキソルビシン単剤による治療を開始した。有害事象によるperformance status低下にて,2コースでパゾパニブへ変更した。その後,二次治療のパゾパニブ5か月,三次治療のエリブリンは2.5か月で病勢進行を認めた。2016年7月より四次治療のトラベクテジンによる加療を開始し1年6か月が経過しているが,多発肝転移巣の一部は縮小も認め,特に重篤な有害事象はなく現在も治療継続中である。文献的な考察も加え報告する。